Abstract
Determination of individual pharmacokinetics in patients undergoing radiopharmaceutical therapy is essential to define critical normal organ dosimetry. Review of a 20 year single institution experience demonstrates practical methodology for routinely characterising pharmacokinetics in each patient and calculating safe, effective therapeutic activities predicated upon prescribed radiation absorbed doses to the critical organs. In particular the results achieved in over 100 unselected consecutive clinic patients treated with 131I-rituximab radioimmunotherapy for relapsed/refractory non- Hodgkins lymphoma have matched the ORR of 75% and CR 50% achieved in formal phase II clinical trial. The low level of myelotoxicity was attributed to prospective dosimetry in each patient and prescribed dose of 0.75 Gy to whole body. Radiopeptide therapy of progressive neuroendocrine tumours with 177Lu-octreotate, illustrates application of practical dosimetry using retrospective quantitative imaging to define individual pharmacokinetics. Further challenges of multimodality combination therapy using radionuclide cocktails, chemotherapy and antivascular therapy, which will perturb pharmacokinetics, will require creative dosimetric methodology for continued safe, effective clinical practice of therapeutic nuclear oncology.
Keywords: Radiopharmaceutical pharmacodynamics, Radionuclide dosimetry, Therapeutic Nuclear Oncology, Lutetium- 177, Rhenium-188
Current Pharmaceutical Design
Title: Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
Volume: 15 Issue: 9
Author(s): J. Harvey Turner
Affiliation:
Keywords: Radiopharmaceutical pharmacodynamics, Radionuclide dosimetry, Therapeutic Nuclear Oncology, Lutetium- 177, Rhenium-188
Abstract: Determination of individual pharmacokinetics in patients undergoing radiopharmaceutical therapy is essential to define critical normal organ dosimetry. Review of a 20 year single institution experience demonstrates practical methodology for routinely characterising pharmacokinetics in each patient and calculating safe, effective therapeutic activities predicated upon prescribed radiation absorbed doses to the critical organs. In particular the results achieved in over 100 unselected consecutive clinic patients treated with 131I-rituximab radioimmunotherapy for relapsed/refractory non- Hodgkins lymphoma have matched the ORR of 75% and CR 50% achieved in formal phase II clinical trial. The low level of myelotoxicity was attributed to prospective dosimetry in each patient and prescribed dose of 0.75 Gy to whole body. Radiopeptide therapy of progressive neuroendocrine tumours with 177Lu-octreotate, illustrates application of practical dosimetry using retrospective quantitative imaging to define individual pharmacokinetics. Further challenges of multimodality combination therapy using radionuclide cocktails, chemotherapy and antivascular therapy, which will perturb pharmacokinetics, will require creative dosimetric methodology for continued safe, effective clinical practice of therapeutic nuclear oncology.
Export Options
About this article
Cite this article as:
Turner Harvey J., Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787582020
DOI https://dx.doi.org/10.2174/138161209787582020 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Computational Modeling and Simulation of the Bcl-2 Family: Paving the Way for Rational Drug Design
Current Medicinal Chemistry Tanshinone IIA Protects Hippocampal Neuronal Cells from Reactive Oxygen Species Through Changes in Autophagy and Activation of Phosphatidylinositol 3-Kinase, Protein Kinas B, and Mechanistic Target of Rapamycin Pathways
Current Neurovascular Research Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Ectopic Lymphoid Neogenesis and Lymphoid Chemokines in Sjogren’s Syndrome: At the Interplay between Chronic Inflammation, Autoimmunity and Lymphomagenesis
Current Pharmaceutical Biotechnology Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
Current Drug Targets E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma
Current Pharmaceutical Biotechnology The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry Analysis of Comparative Proteomic and Potent Targets of Peniciketal A in Human Acute Monocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design Complement System in SLE as a Target for Antibodies
Current Rheumatology Reviews Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and Prediction
Current Pharmaceutical Biotechnology DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Design, Synthesis and Bioactivities of Phenylamino-Pyrimidine Derivatives as Novel Protein Tyrosine Kinase Inhibitors
Letters in Drug Design & Discovery Modulation of Gene Transcription by Natural Products - A Viable Anticancer Strategy
Current Pharmaceutical Design The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design The Control of Cell Cycle in Mouse Primordial Germ Cells: Old and New Players
Current Pharmaceutical Design 99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents
Anti-Cancer Agents in Medicinal Chemistry